Aclaris Therapeutics (ACRS) Cash from Investing Activities (2014 - 2026)

Aclaris Therapeutics' Cash from Investing Activities history runs 13 years deep, the most recent figure standing at -$30.9 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 261.79% year-over-year to -$30.9 million in Q1 2026; TTM through Mar 2026 was -$1.7 million, a 97.5% increase from a year earlier, with the FY2025 full-year figure at $48.4 million, up 169.32% from the prior year.
• Cash from Investing Activities fell to -$30.9 million in Q1 2026 per ACRS's latest filing, from $10.4 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $32.5 million in Q3 2023 and bottomed at -$88.7 million in Q4 2024.
• The 5-year median for Cash from Investing Activities is $5.0 million (2025), against an average of $383058.8.
• Across the five-year window, Cash from Investing Activities soared 2573.29% in 2023 and plunged 1275.14% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at $2.7 million in 2022, then soared by 179.42% to $7.6 million in 2023, then plunged by 1275.14% to -$88.7 million in 2024, then jumped by 111.69% to $10.4 million in 2025, then sank by 398.31% to -$30.9 million in 2026.
• Per Business Quant, the three latest ACRS Cash from Investing Activities figures stand at -$30.9 million (Q1 2026), $10.4 million (Q4 2025), and $13.8 million (Q3 2025).